Argireline
- Category
- Skin & Cosmetic
- Administration routes
- Topical
- Regulatory status
- Cosmetic ingredient
What it is
A synthetic hexapeptide sold in cosmetic serums as a needle-free alternative to botulinum toxin for crow's feet and expression lines. Human evidence for modest wrinkle reduction is moderate and tolerability looks favorable, but efficacy is inconsistent, skin penetration is doubtful given the peptide's size, and claims it rivals botox are speculative. It is a cosmetic ingredient, not an approved drug, carries no FDA approval, and purity varies among products.
Read Full recordStudied uses & evidence
Studied uses(5)
Reduction of expression wrinkles (crow's feet, forehead lines, periorbital wrinkles)
MediumA small human RCT showed significant wrinkle reduction versus placebo, but replication is lacking.
Non-invasive alternative to botulinum toxin injections
SpeculativeNo head-to-head human trials exist; topical form does not reach facial muscle tissue.
Favorable safety and tolerability profile
MediumSmall human studies report good tolerability at low concentrations, with no serious adverse events.
Evidence limits
- Evidence Level
- Moderate
Clinical evidence for Argireline is mixed. Early studies used subjective ratings and objective skin-replica measurements. The 2013 RCT reported a 48.9% subjective response rate and improved objective roughness measures. However, a more recent study using objective Visia imaging found no statistically significant effect attributable to Argireline specifically (both sides received hyaluronic acid serum, and neither within-side improvement was statistically significant). The fundamental limitation is extremely poor skin penetration (<0.2% in 24 hours), which raises questions about whether bioactive concentrations reach neuromuscular targets. Safety evidence is consistently strong across all studies.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(5)
Risks = level of concern: High · Moderate · Low · Theoretical
Minimal skin penetration
HighMild local irritation
LowInjection-related adverse events
ModerateInconsistent clinical efficacy
HighPotential for exaggerated marketing claims
High
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.